Drug intelligence / Profile preview

lactobacillus crispatus lcr86

Development stage: Unknown
Lead developer: Wecare Probiotics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus crispatus LCr86 is a specific probiotic strain developed by Wecare Probiotics for the management of vaginal dysbiosis. Administered as an oral supplement, LCr86 is designed to colonize the vaginal environment and restore a healthy microbiome, particularly in women with intermediate vaginal microbiota (Nugent scores 4-6). The strain works by producing lactic acid, which lowers vaginal pH, and by competing with pathogenic bacteria such as Gardnerella vaginalis. Clinical evaluation focuses on its ability to reduce Nugent scores, improve vaginal microecology, and modulate serum inflammatory cytokines.

Other names: Lactobacillus crispatus LCr86

Beyond the preview

Go deeper on lactobacillus crispatus lcr86.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus crispatus lcr86.

Explore the full profile